Biomimetic Nanoparticles Enabled by Cascade Cell Membrane Coating for Direct Cross‐Priming of T Cells
Abstract
Despite the activation of T lymphocytes by antigen‐presenting cells being responsible for eliciting antigen‐specific immune responses, their crosstalking suffers from temporospatial limitations and endogenous influencing factors, which restrict the generation of a strong antitumor immunity. Here, cascade cell membrane coating is reported to prepare biomimetic nanoparticles (BNs) that can manipulate the cross‐priming of T cells. BNs are obtained from coating nanoparticulate substrates with cell membranes extracted from dendritic cells (DCs) that are pre‐pulsed with cancer cell membrane‐coated nanoparticles. With a DC membrane that presents an array of cancer cell membrane antigen epitopes, BNs inherit the intrinsic membrane function of DCs, which can directly cross‐prime T cells and provoke robust yet antigen‐specific antitumor responses in multiple mouse models. Combination with clinical anti‐programmed death‐1 antibodies demonstrates a robust way of BNs to achieve desirable tumor regression and survival rate. This work spotlights the impact of nanoparticles on direct cross‐priming of T cells and supports a unique yet modulate platform for boosting an effective adaptive immunity for immunotherapy.Keywords
All Related Versions
Funding Information
- National Key Research and Development Program of China (SQ2021YFA090162)
- National Natural Science Foundation of China (21875135)
This publication has 47 references indexed in Scilit:
- Human cell‐based artificial antigen‐presenting cells for cancer immunotherapyImmunological Reviews, 2013
- Nanoengineering Approaches to The Design of Artificial Antigen-Presenting CellsNanomedicine, 2013
- A biomimetic nanosponge that absorbs pore-forming toxinsNature Nanotechnology, 2013
- Mechanisms of Action of AdjuvantsFrontiers in Immunology, 2013
- Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platformProceedings of the National Academy of Sciences, 2011
- Targeted Nanoparticles Deliver siRNA to MelanomaJournal of Investigative Dermatology, 2010
- Artificial Antigen-Presenting Cells for Use in Adoptive ImmunotherapyThe Cancer Journal, 2010
- Limited Amounts of Dendritic Cells Migrate into the T-Cell Area of Lymph Nodes but Have High Immune Activating Potential in Melanoma PatientsClinical Cancer Research, 2009
- Defective Human Leukocyte Antigen Class I-associated Antigen Presentation Caused by a Novel β2-Microglobulin Loss-of-function in Melanoma CellsJournal of Biological Chemistry, 2006
- Tumor-derived lactic acid modulates dendritic cell activation and antigen expressionBlood, 2006